GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

The FDA has released draft guidance that aims to clear up how drug developers can use alternative testing – but that doesn’t ...

Eli Lilly disclosed that retatrutide, its experimental triple hormone receptor agonist, hit the primary and all key secondary ...

No one has set foot on the moon since America left in 1972. NASA is heading there again, but hasn't explained why the trip ...

India vs Afghanistan: The Board of Control for Cricket in India has opted for a high-intensity approach to the upcoming ...

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in type 2 diabetes (T2D) to go with its earlier encouraging data as a weight-loss therapy. The GIP, GLP-1 and glucagon agonist ...

Cricket Australia on Sunday unveiled its 2026-27 international calendar with a packed itinerary leaving little turnaround time ahead of the marquee Border-Gavaskar Trophy in India, expected to begin ...

Alto Neuroscience secures $120M to advance novel depression therapy ALTO-207 through Phase 3 trials, aiming for FDA ...

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

Strong Buy on 2025 sales growth, pipeline acquisitions like Synnovation, and drivers offsetting 2026 patent cliffs—read more ...

The John Day City Council and Urban Renewal Board agreed to a settlement with Iron Triangle for the final plat of Ironwood Estates Phase 2. The city […] ...

Resolution Minerals is preparing to embark on a major diamond drilling program to test the scale of the Golden Gate ... Read More The post Resolution’s upcoming diamond drill program to test scale of ...